Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis by Shi Qingping et al.
Qingping et al. BMC Infectious Diseases 2013, 13:160
http://www.biomedcentral.com/1471-2334/13/160RESEARCH ARTICLE Open AccessDrug use evaluation of cefepime in the first
affiliated hospital of Bengbu medical college:
a retrospective and prospective analysis
Shi Qingping1,2*†, Ding Feng1†, Sang Ran1†, Liu Yan1†, Yuan HaoYu3† and Yu Meiling1†Abstract
Background: Cefepime is a fourth generation cephalosporin antimicrobial. Its extended antimicrobial activity and
infrequent tendency to engender resistance make it popular for the treatment of infections. However, proper use of
cefepime has not been studied adequately. In this study, we used a retrospective cohort and a prospective cohort
to evaluate the usage pattern, adverse effects and cost-effectiveness of cefepime by conducting a drug use
evaluation (DUE) program in the First Affiliated Hospital of Bengbu Medical College, Anhui, China.
Methods: The DUE criteria for cefepime were established by applying literature review and expert consultation, an
effective method to promote interventions that will improve patient outcomes and the cost-effectiveness of drug
therapy. According to the criteria, we performed a cross-sectional retrospective (cycle A) study on 96 hospitalized
patients who received cefepime treatment and a prospective (cycle B) study on 111 hospitalized patients with
cefepime treatment intervention. After identifying problems with usage and completing a cefepime use evaluation
for cycle A, 2 months of educational intervention among professionals were given and a more effective and
rational system of cefepime use was set up. During the 2 months, the lectures were arranged and attendance of
prescribers was required.
Results: The data from cycle A showed that the biggest problem was irrational prescription of cefepime; bacterial
culture and drug sensitivity tests for cefepime were also not carried out. Following 2 months of educational
intervention among professionals, the results for cycle B showed that the correct indication rate was 94.59%,
compared with 84.38% in cycle A. Use of bacterial culture and sensitivity tests also improved, by 88.29% in cycle B
compared with 65.22% in cycle A. Compared with cycle A, the significantly improved items (P < 0.05) in cycle B
were blood examination, liver function monitoring, renal function monitoring, dose and duration, dosing frequency
and correct medication combinations.
Conclusions: Cefepime can be used appropriately for the right indications and in a cost-effective way for the
majority of patients through educational intervention, including the special precautions that must be followed for
appropriate dosing frequency and duration. DUE programs will become one model of hospital pharmacy care and
part of the plan for continuous improvements to the quality of health care in China.
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Cefepime is a fourth generation cephalosporin anti-
microbial with a wide spectrum of antimicrobial activity,
high penetration, and stability against most β-lactamases
[1]. Researchers have verified that cefepime tends to be
more effective than ceftazidime. Because of its extended
antimicrobial activity and infrequent tendency to engen-
der resistance, cefepime is popular for the treatment of
infections and is widely used to treat severe nosocomial
pneumonia, as well as for empirical treatment of febrile
neutropenia, uncomplicated and complicated urinary
tract infections, uncomplicated skin and skin structure
infections, and complicated intra-abdominal infections
[2,3]. However, it should be used judiciously because un-
necessary, improper, and prolonged use may lead to the
emergence of cefepime-insensitive bacteria and risk de-
cline in its efficacy [4].
The concept of the drug use review (DUR) was raised
by the Joint Commission on Accreditation of Healthcare
Organizations (JCAHO) [5,6]. Subsequently, the drug use
evaluation (DUE) was developed on the basis of the DUR.
The DUE is an ongoing, systematic process designed to
promote the appropriate and effective use of drugs. The
purpose is to detect potential problems and improve drug
use. The DUE contains qualitative measures and empha-
sizes the outcomes and cost-effectiveness of drug therapy.
According to the DUE criteria for cefepime published by
the American Society of Hospital Pharmacists (ASHP), a
cefepime regimen should be restricted to the following in-
dications [7]: 1. Treatment of severe infection caused by
suspected gram-negative bacteria or mixed aerobic bac-
teria (including Pseudomonas aeruginosa, except for cen-
tral nervous system infections) in hospitalized patients,
but not used for infection caused by suspected anaerobic
bacteria, enterococci or pivmecillinam-resistant staphylo-
coccal infection; and 2. Treatment of the following con-
firmed infections: urinary tract infections, respiratory
tract infections, infections of the skin and subcutaneous
tissue; infective endocarditis; osteomyelitis; pathogen in-
fection and bacteremia caused by susceptible organisms
sensitive to cefepime, but resistant to other more toxic
but less expensive drugs.
To study the current status of cefepime use in the
First Affiliated Hospital of Bengbu Medical College, data
were collected from patients who received cefepime
treatment. In the present study, we performed a histor-
ical cohort study (cycle A) on 96 hospitalized patients
who received cefepime treatment. Following 2 months
of educational intervention among professionals, we
performed a prospective (cycle B) study on 111 hospital-
ized patients with cefepime treatment intervention. Fi-
nally, an effective and rational system of cefepime use
was set up in the First Affiliated Hospital of Bengbu
Medical College.Methods
Study setting
The First Affiliated Hospital of Bengbu Medical College
is a 1936-bed tertiary care facility in Anhui, China. The
hospital includes all major departments and services, in-
cluding five pediatric wards and four geriatric wards,
hematology and oncology pediatrics, 14 surgical depart-
ments, laboratory, X-ray, ultrasound scanner and elec-
trocardiogram, pharmacy, etc. The study was approved
by the Department of Health of Anhui Province in
China, and the DUE criteria for cefepime and the DUE
procedure were approved by the Drug and Therapeutics
Committee (DTC) of the hospital.
Study design
The study duration was divided into two periods (cycle A
and cycle B). Cycle A was a cross-sectional retrospective
study on 96 hospitalized patients selected because they
had received cefepime treatment, performed from June
2011 to October 2011 through access to electronic med-
ical records or medical case records to obtain cefepime
use information once patients were discharged from the
hospital. After identifying problems with use and com-
pleting a cefepime use evaluation for cycle A, 2 months of
educational intervention among professionals was given
and a more effective and rational system of cefepime use
was set up. The 2-month educational intervention was
carried out in November and December of 2011. During
these 2 months, lectures were arranged and attendance of
prescribers was required. To promote standardization in
the management and clinical use of cefepime, clinical
pharmacists and infectious disease experts carried out a
number of these trainings for clinicians about the know-
ledge and clinical use of antibacterial drugs and their man-
agement through the organization of a sub-committee of
the DTC, the Antibacterial Drug Management Team. For
cycle A, a data collection chart was designed and ap-
proved by the Antibacterial Drug Management Team in
the hospital. The chart included the items of demograph-
ics, type of surgical procedure, drug history, drug allergy,
choice of antibiotic drug, dose, time of administration,
number of doses, medications combined with cefepime,
and replacement drugs. Conducted under the new system,
a prospective (cycle B) study on 111 hospitalized patients
with a cefepime treatment intervention selected at ran-
dom was performed from January 2012 to May 2012. In
cycle B, the planned drug therapy was evaluated before
the patient received the first dose and all items were
recorded as mentioned for cycle A. During the prospective
study, most of the doctors were the same as those present
during June to October 2011. According to the DUE cri-
teria, the usage pattern, adverse effects, and cost-
effectiveness of cefepime were compared between cycle A
and cycle B.
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The inclusion criteria included those who received
cefepime during their hospitalization in the study pe-
riods. For those with repeated cefepime courses, an
interval of less than 15 days was considered as a single
administration, while an interval of more than 15 days
was considered as multiple administrations. The exclu-
sion criteria were not specific.
Definitions
The DUE was performed according to the guidelines
published by the ASHP [8]. In brief, the DUE consisted
of the following eight steps: 1. to confirm the medicine
and/or disease for evaluation; 2. to establish the DUE
criteria and indications; 3. to gain the approval of the
medical authorities (such as the hospital and/or the
DTC); 4. to collect the data for drug use; 5. to rectify the
drug administration pattern through education interven-
tion; 6. to complete the second-round evaluation of the
medicine; 7. to optimize the drug administration pattern
and methods; and 8. to rectify the evaluation criteria and
summarize the clinical experiences. The detailed steps of
the DUE for our study are summarized in Figure 1.
According to the literature [9-13], the evaluation cri-
teria for drug use include the following information:
1. diagnosis standards; 2. contraindications of the drug;
3. drug interaction standards; 4. drug administration stan-
dards; 5. treatment duration and drug dosage; 6. drugTo confirm the medicine and/or disease for ev
To establish the DUE criteria of cefepi
Data collection
Drug use evaluation
To rectify the administration pattern
To rectify and optimize DUE
Drug use re-evaluation and re-interve
To evaluate efficiency, ADR and cost-effec
To optimize the criteria
To summarize the clinical experience
To coordinate with the corresponding depa
Figure 1 The diagram of the drug use evaluation of cefepime.dosage per day; and 7. appropriate or inappropriate stan-
dards. Besides these standards, some other evaluation in-
dices are needed to identify the accuracy of the collected
data.
Data analysis
The collected data were cleaned, categorized and ana-
lyzed using SPSS for Windows version 15.0. Proportions
were compared using the χ2 or Fisher’s exact test, where
appropriate. Continuous variables were compared by
the Student’s t-test. All P values were two-tailed, and
P < 0.05 was considered statistically significant.
Ethics
This study was approved by the Department of Health of
Anhui Province in China and the Ethics Committee of
The First Affiliated Hospital of Bengbu Medical College.
The need for informed consent for this study was waived
by the ethics committee.
Results
Study population and patient characteristics
From hospitalized patients with infectious diseases, a
total of 207 patients in cycle A and cycle B were identi-
fied according to the DUE criteria. In the study, the
median age was 40.2 ± 15.3 years with an inter-quartile
range from 5 months to 83 years in cycle A, while in





According to the 
evaluation results
To establish the inclusion and 
exclusion criteria as well as data 
To gain the approval of DTC
1.To draft the initial criteria
2.Consult the senior experts
rtments
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tios of men to women were 50:46 and 61:50, respect-
ively. No significant differences were noted between the
clinical data (P > 0.05).
After educating the professionals, Table 1 shows that
the correct indication rate in cycle B was 94.59% com-
pared with 84.38% in cycle A. Professionals demonstrated
improved awareness for performing bacterial culture and
sensitivity tests, as shown in Table 1, with 88.29% in cycle
B compared with 65.22% in cycle A. With regards to drug
monitoring and dosage, aspects that were improved in
cycle B compared with cycle A included life index record
(including basic patient characteristics such as height,
body weight, body temperature, blood pressure, etc.), drug
skin test, solvent selection (the choice of IV solution
to use as the carrier of the cefepime infusion), route
of administration, and compatibility. The significantly
improved items in cycle B were blood examination
(88.54% in cycle A and 97.30% in cycle B, P < 0.05),
liver function monitoring (78.12% and 90.99%, respect-
ively, P < 0.05), renal function monitoring (75.00% and
96.40%, respectively, P < 0.05), dose and duration (72.92%
and 90.09%, respectively, P < 0.05), dosing frequency
(72.92% and 90.09%, respectively, P < 0.05) and correct
medication combinations (62.37% and 82.18%, respect-
ively, P < 0.05). With regard to replacement drugs, there
was no significant improvement in cycle B (P > 0.05).
Table 1 shows that most items showed improved outcomesTable 1 Drug use evaluation of cefepime in 96 and 111 patie
Items Number of patients (with the standar
Indication 81 (84.38
Drug monitoring
Life index record 96 (100
Blood examination 85 (88.54
Liver function monitoring 75 (78.12
Renal function monitoring 72 (75.00
Bacterial culture and sensitivity test 60 (65.22
Drug skin test 96 (100
Dosage
Dose and duration 70 (72.92
Dosing frequency 70 (72.92
Solvent selection 96 (100.0
Route of administration 96(100.0
Compatibility 95 (98.96
Replacement drugs 84 (87.50
Combined medication (drug-drug interaction) 58 (62.37
Adverse drug reactions 8 (8.33%
Outcome 83 (91.21
*Some cases could not be evaluated, and the percentage was calculated from the cin cycle B, although a few items showed no significant
improvement.
Most prescribers demonstrated appropriate knowledge
regarding cefepime’s prescribing, giving it for the right
indications and in proper doses. The appropriate dosing
frequency is every 8 h or 12 h, yet dosing frequency was
performed less well in both cycles and the most com-
mon error of dosing frequency and dosage was one day’s
dose IV every 24 h (Table 1). Cefepime has poor oral ab-
sorption and poor stability. Hence dosage was most
commonly administered by injection. The prescribers
were asked their opinions on whether the therapy
was cost-effective. An average of about 80% of the
prescribers in both cycles were judged to be using the
therapy in a cost-effective way, which suggests that
cefepime use was appropriate (Table 2). The study
suggests that cefepime was being used appropriately
for the right indications in the majority of patients in
cycle B following the educational intervention (Table 1)
and Table 2 suggests that the cost-effectiveness was the
same in cycles A and B, so that the intervention had no
effect on this.
Medications combined with cefepime
Combinations of cefepime with fluoroquinolones and
macrolides were widely used in the project. Triple therapy
is generally used to cure severe infections or mixed in-
fections, which two antimicrobials alone cannot control,nts during cycle A and cycle B, respectively
of 96) consistent
ds in cycle A
Number of patients (of 111) consistent with

















ases that could be evaluated.
Table 2 Cost-effectiveness of therapy as assessed by 38
prescribers during cycle A and cycle B




Yes 30 (78.95%) 31 (81.58%)
No 5 (13.16%) 5 (13.16%)
Sometimes 3 (7.89%) 2 (5.26%)
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cycle A, irrational combinations using cefepime were doc-
umented; for example, five patients had peri-operative
period prophylactic cefepime treatment in combination
with a quinolone antibiotic. After the education interven-
tion, the results in Table 1 show that medications com-
bined with cefepime tended to be more rational, with
appropriate combinations in 89 (80.18%) out of 111 in
cycle B compared with 58 (62.37%) out of 96 in cycle A.
Adverse drug reactions
The most common adverse reactions with cefepime were
nausea (2.42%), skin rash (2.42%), headache (1.44%), and
diarrhea (0.48%), as shown in Table 3. Both Tables 1 and
3 show reduced adverse drug reactions in cycle B after
the educational intervention.
Resistance
Acquired microbial resistance to cefepime within healthcare
facilities such as some hospitals is a growing problem
[14]. The dosage, dosing frequency, duration of therapy
and alternative drugs are factors contributing to the in-
creased resistance. As shown in Table 1, compared with
cycle A, rates of appropriate dosage, dosing frequency,
duration of therapy and alternative drugs improved sig-
nificantly in cycle B.
Discussion
The results of the present study show that the usage pat-
tern, adverse effects and cost-effectiveness of cefepime
can be improved significantly by conducting a DUE pro-
gram. An effective and rational system of cefepime use
was established in the First Affiliated Hospital of Bengbu







Headache 2 (2.08%) 1 (0.90%)
Nausea 2 (2.08%) 3 (2.70%)
Skin rash 2 (2.08%) 3 (2.70%)
Diarrhea 1 (1.04%) 0 (0%)
Other 1 (1.04%) 0 (0%)
None 88 (91.67%) 104 (93.69%)In the study, data were collected according to DUE
criteria to assess the clinical appropriateness, cost-
effectiveness and effective use of the drug therapy.
The study that we conducted showed that cefepime is
the drug of choice for severe gram-negative bacterial
infections caused by susceptible aerobic bacteria (including
Pseudomonas aeruginosa) and is being used in the majority
of the public sector teaching hospitals according to its cli-
nical indications, but not for infections caused by suspected
anaerobic bacteria, enterococci, or pivmecillinam-resistant
staphylococci, etc. Cefepime therapy proved to be cost-
effective. Most hospitals exercise special control over this
drug and its off-label use is prohibited in many hospitals in
China. Thus cefepime used for prophylaxis was not listed
in the criteria of this study or of the ASHP. In our study,
justifications for prescribing cefepime were: 1. treat-
ment of moderate and severe infections caused by
suspected gram-negative bacteria or mixed aerobic bacteria
(including Pseudomonas aeruginosa), but not for infection
caused by suspected anaerobic bacteria, enterococci or
pivmecillinam-resistant staphylococci; 2. alone or in com-
bination with other antibacterial drugs to treat moderate
and severe infections caused by sensitive bacteria including:
lower respiratory tract infection (pneumonia and bron-
chitis); simple lower urinary tract infection and complicated
urinary tract infections (including pyelonephritis); uncom-
plicated skin and skin and soft tissue infections; compli-
cated intra-abdominal infection (including peritonitis and
biliary tract infection in obstetrics and gynecology); sepsis;
endocarditis for adults and 2-month to 16-year-old chil-
dren; 3. empirical treatment of patients with neutropenia
associated with fever; and 4. empirical treatment of the
above suspected infections, although not recommended as
the first-line treatment drug, unless other antimicrobials
are ineffective. Compared with the ASHP criteria for
cefepime, there were some adjustments in our criteria
[14-16]. First, it is not recommended for osteomyelitis
because of its lower concentration in the bone marrow.
Second, bacterial culture and drug sensitivity tests are not
widely used clinically, so these results are unable to guide
clinical use. It is also very important to use cefepime empir-
ically for the treatment of neutropenia and fever, which was
added to our criteria.
The growing resistance of bacteria to antimicrobials,
including cefepime, has been shown to be a very import-
ant problem. The following bacteria are associated with
varying degrees of resistance to cefepime: Staphylococcus
aureus, Staphylococcus epidermidis, Streptococcus faecalis,
some even up to 100%, and Acinetobacter baumannii and
Escherichia coli up to 97.3% [17,18]. With cefepime as
the specific designated antibiotic drug for serious gram-
negative bacteria or mixed aerobic bacterial infections,
there is the growing prospect that resistance will result in
a return to the days when fatal bacterial infections were
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duration of therapy and alternative drugs are contributing
factors to increased resistance. In cycle A, we found that
excessive doses or inappropriate dosing frequencies of
cefepime regimens were used. The most common dose
and dosing frequency error was that an entire day’s dose
was used in patients at one time, probably because of
staff nurses’ workload. Irrational alternative drugs and un-
necessary, improper and prolonged use were also pres-
ent because of incorrect prescriptions from professionals.
Through our cefepime use intervention to educate profes-
sionals to use cefepime correctly, improved outcomes for
many of these problems were observed in cycle B.
The most common adverse reactions to cefepime are
headache, nausea, skin rash and diarrhea [19,20]. The
adverse effects induced by cefepime therapy are shown
in Table 3. In cycle B, we found that if due care was
given and/or the infusion time was 15–30 min, the ad-
verse effects could be avoided. However, the staff nurses
are in a hurry because of their workload and they usually
administer the drugs rapidly, which results in adverse re-
actions. To strengthen safety supervision, adjustments
were given by us to them, including: first, increasing the
observation and treatment of rare adverse reactions
(such as toxic nephrosis and renal dysfunction), while
emphasizing the detection and specific treatment mea-
sures for different types of adverse reactions; second,
promoting clinical experience to prevent the possibility
of adverse reactions occurring (such as the use of antibi-
otics in patients along with the timely use of intestinal
microecological preparations, according to the drug in-
structions) [16]. The reasons for adding these items are
that: 1. the ADR reporting system should be made more
efficient to minimize the incidence of adverse effects
during the therapy; 2. in our healthcare setup, the major-
ity of the ADRs are unnoticed; 3. patients should be
given sufficient information regarding their medicines
so that they can identify any abnormal finding in their
course of therapy [21,22]; 4. the effectiveness of cefepime
therapy can be enhanced and the adverse effects can be
avoided to some extent by more vigilant and positive
attitudes among prescribers, nurses and pharmacists.
This requires a more collaborative practice among physi-
cians and pharmacists so that pharmacists can guide
physicians to the rational prescription and safer use of
medicines.
Conclusions
Comparisons were made between the two periods of
cefepime use, between which we set up more reasonable
cefepime use criteria in the First Affiliated Hospital of
Bengbu Medical College, Anhui, China. Our study sug-
gests that we detected potential problems and improved
cefepime use through the DUE program. We believe thatthe new criteria will assist professionals to use cefepime
more correctly in the future and that the DUE program
will become a model of hospital pharmacy care and part
of the plan for continuous improvements to the quality
of health care in China.
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